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A B S T R A C T

Background: Current point-of-care tests (POCT) for syphilis, based on the detection of Treponema pallidum
(TP) total antibodies, have limited capacity in distinguishing between active and past/treated syphilis. We
report the development and early evaluation of a new prototype POCT based on the detection of TP-IgA antibodies, a novel biomarker for active syphilis.
Methods: The TP-IgA POCT (index test) was developed in response to the World Health Organisation (WHO)
target product proﬁle (TPP) for a POCT for conﬁrmatory syphilis testing. Two sub-studies were conducted
consecutively using 458 pre-characterised stored plasma samples in China (sub-study one, addressing the
criteria for the WHO TPP), and 503 venous blood samples collected from pregnant/postpartum women in
South Africa (sub-study two, addressing potential clinical utility). Performance of the index test was assessed
against standard laboratory-based serology using a combination of treponemal (TPHA) and non-treponemal
(rapid plasma reagin [RPR]) tests.
Findings: In sub-study one, the index test demonstrated 96¢1% (95%CI=91¢7%-98¢5%) sensitivity and 84¢7%
(95%CI=80¢15 88¢6%) speciﬁcity for identiﬁcation of active syphilis (TPHA positive, RPR positive). It correctly
identiﬁed 71% (107/150) samples of past-treated syphilis (TPHA positive, RPR negative). In sub-study two,
the index test achieved 100% (95%CI=59%-100%) sensitivity for active syphilis and correctly identiﬁed all nine
women with past syphilis.
Interpretation: The TP-IgA POCT has met the WHO TPP for a POCT for diagnosis of active syphilis and demonstrated its potential utility in a clinical setting. Future studies are warranted to evaluate ﬁeld performance of
the ﬁnal manufactured test.
Funding: Saving Lives at Birth: Grand Challenge for Development, Thrasher Research Fund, and the Victorian
Government Operational Infrastructure Scheme.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Research in context
Evidence before this study
Maternal and congenital syphilis has re-emerged as a global
health challenge. In resource-constrained settings, limited
availability and lack of access to conﬁrmatory testing of active
infection constrain efforts to prevent congenital syphilis. We
searched PubMed to identify peer-reviewed articles reporting
performance of POCTs that can be used for conﬁrmatory testing
of active syphilis. We found that the Dual Path Platform (DPP)
Screen & Conﬁrm Assay is the only POCT with ﬁeld evaluation
data but has limited capacity in distinguishing between active
and past/treated syphilis.
Added value of this study
This is the ﬁrst study to assess diagnostic performance and clinical utility of a newly developed TP-IgA POCT for conﬁrmatory
syphilis testing. Results of this study provide empirical evidence showing that when used in combination with standard
TP screening methods, the new conﬁrmatory test has capacity
to identify past syphilis whilst maintaining a high sensitivity
for active syphilis infections compared to other POCTs on the
market. This ﬁnding represents a signiﬁcant development in
the POC diagnostic landscape for syphilis, supporting the global
effort in prevention of mother to child transmission and elimination of congenital syphilis in settings where laboratory
capacity is limited.
Implication of all the available evidence
Data from the WHO global sexually transmitted infection surveillance suggest that the global targets for screening and treatment of syphilis among pregnant women are not being met
with only 18/194 (9%) of countries have achieved at least 95%
of pregnant women screened for syphilis and 95% who tested
positive receiving treatment. Low and middle-income countries
(LMICs) with limited resources for health face the greatest challenges. Current, commonly used rapid POCTs for syphilis have
limited capacity in distinguishing between active and past
infections, leading to over-treatment and further strains on
health care resources. The availability of the TP-IgA POCT as a
conﬁrmatory test for women initially reactive with a screening
POCT will provide more options for LMICs to enhance effective
and efﬁcient use of limited health system resources for screening, diagnosis and treatment of active syphilis among pregnant
women.

1. Introduction
Syphilis is a curable sexually transmitted infection (STI), caused by
the bacterium Treponema pallidum (TP). Globally, an estimated six
million new cases of syphilis are diagnosed annually, most of the
infections occur in low and middle-income countries (LMICs) and
congenital syphilis is not uncommon [1]. An analysis on trend over
time of syphilis in 132 countries showed that between 2012 and
2016, the prevalence of active syphilis in women of reproductive age
(15 to 49 years) had increased in 78 countries, of which 10 (13%)
were substantive (10% proportionally, 0.10% percentage-point
absolute difference and non-overlapping 95% conﬁdence intervals in
2012 and 2016) whilst among 54 countries with observed decreased
prevalence only ﬁve (9%) countries experienced a substantive
decrease [2].

Treatment of syphilis is relatively simple, effective and inexpensive with one dose of Benzathine penicillin [3]. However, diagnosis
of active syphilis, particularly in LMICs, is often challenging due to
the persistence of IgG antibodies to TP after prior treated syphilis
infections, which necessitates a combination of treponemal (e.g.
TPHA, TPPA) and non-treponemal (e.g. RPR) tests to distinguish
active from past treated infections. Availability and introduction of
point-of-care tests (POCTs) has increased access to testing for syphilis; however, current POCTs for serological diagnosis of syphilis only
detect IgG or both IgG and IgM antibodies speciﬁc to TP. It is known
that serological tests based on IgG cannot distinguish between
active and treated infections, and IgM tests can be highly sensitive
in symptomatic patients but have suboptimal sensitivity in asymptomatic cases [4].
The Dual Path Platform (DPP) Syphilis Screen & Conﬁrm test
(Chembio Diagnositcs, Medford, NY, USA) is the ﬁrst commercially
available rapid POCT that gives both treponemal and non-treponemal
results that assist in distinguishing between current and past infection [5]. However, marked variation in diagnostic performance of the
test has been reported particularly in the sensitivity and speciﬁcity of
the non-treponemal component [5,6]. A laboratory evaluation in Australia [7] reported that 49¢8% (105/211) presumptive past treated
serum samples were misclassiﬁed as active syphilis by the DPP test,
whereas a ﬁeld evaluation among pregnant women in Burkina Faso
[8] showed 48¢4% (44/91) women with active syphilis would be undiagnosed had the DPP test been used. The difference in test performance can be partly explained by the lot-to-lot variation as a
laboratory study in the United States[9] showed a signiﬁcant difference in the sensitivity for the non-treponemal component of the DPP
in two different lots studied - 65¢3% (95%CI: 60¢5 69¢8) and 80¢9%
(95%CI: 72¢6 87¢2) respectively.
Given that the re-emergence of a syphilis epidemic among pregnant women and key populations is a global health concern [10],
innovative assays using a biomarker that can accurately distinguish
between past, treated and active infection at the point-of-care (POC)
are need. Access to such an assay will improve diagnosis and facilitate
appropriate treatment in a timely manner [11]. To promote research
and development of reliable, low-cost POCTs for syphilis, the WHO
developed a Target Product Proﬁle (TPP) identifying minimum and
preferred assay performance for screening and conﬁrmation of active
syphilis (and other STIs) [12]. The TPP speciﬁes a minimum clinical
sensitivity of >80% for patients with high-titre RPR (8) and speciﬁcity of >80%, with optimal performance of >90% and >95%, respectively, for screening and conﬁrmation of syphilis infection. The WHO
TPP also highlighted the need for identiﬁcation of new markers for
acute syphilis infection [12]. With these needs in mind, researchers
at the Burnet Institute developed a novel POCT for diagnosis of active
syphilis infection based on detection of TP-speciﬁc IgA antibodies.
Whilst TP-IgG/IgM antibodies have shown some promise as a biomarker for acute syphilis infection, TP-IgA has not been systematically evaluated before. Our laboratory experiments using enzymelinked immunosorbent assays (ELISAs) with conﬁrmed active syphilis
and past syphilis samples revealed two observations that have led to
development of a more sensitive and speciﬁc POCT. Firstly, TP-speciﬁc IgA had higher reactivity rates than IgM in active syphilis samples. Secondly, inclusion of a novel TP antigen (TP0453) [13] along
with the conventional antigens used in most POCTs further boosted
IgA sensitivity, reaching the WHO TPP for conﬁrmation of active
syphilis. These reagents were subsequently incorporated into the TPIgA POCT. During evaluation of early test prototypes using 79 reference plasma samples from the National Serology Reference Laboratory (Melbourne, Australia) the TP-IgA POCT achieved 91¢2%
sensitivity (31/34) for target active syphilis samples, 76% speciﬁcity
(19/25) for samples of past-treated syphilis, and 95% (19/20) speciﬁcity for healthy control (no syphilis) samples, potentially meeting the
WHO TPP (unpublished data).
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In this study we sought to evaluate the performance of the ﬁnal
prototype TP-IgA POCT for detection and differentiation of active
syphilis, ﬁrstly in a reference laboratory setting in China to determine
test performance compared with the WHO TPP, and secondly in an
antenatal clinical setting in South Africa to address potential clinical
utility of the test.

2. Methods
2.1. Test under evaluation
The TP-IgA POCT is a lateral ﬂow, in-house manufactured immunochromatographic test designed to detect TP-speciﬁc IgA class antibodies. The test incorporates a mixture of TP chimeric Recombinant
antigen (TpN15, TpN17, TpN47; Fapon, China) and Tp0453 antigen
(Meridian Life Sciences, USA). It uses 5ml of specimen (whole blood,
plasma or serum), which ﬂows through a membrane where TP-speciﬁc IgA antibodies from the specimen binds with treponemal antigens immobilised on the membrane as a line in the test area marked
“Test line”. Other IgA antibodies (along with other sample constituents) continue migrating along the membrane and immunoglobulins
of IgG, IgM and IgA class (if present) bind with immobilised protein L
in the control line area marked “Control line”. Anti-human IgA colloidal gold is rehydrated and migrates past the treponemal-speciﬁc IgA
bound to the antigens immobilised in the test line area, leading to
the formation of a pink to purple line which conﬁrms a positive test
result. The absence of this line indicates a negative result. Unbound
anti-human IgA gold continues to migrate to the IgA bound to the
control line area, forming a deep pink to purple line. Absence of the
control line indicates an invalid result (if the test has not been performed properly) or the presence of IgA deﬁciency in the patient. The
total testing procedure should take 30 min. (Fig. 1)
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2.2. Study design
Two sub-studies were conducted consecutively at the National
Centre for STD Control in China (NCSC) and the Rahima Moosa
Mother and Child hospital (RMMCH) in South Africa to address the
stated objectives. The NCSC is part of an international network of
clinical and laboratory-based evaluations of sexually transmitted
infection tests. The Centre had experience in laboratory evaluations
and development of recommendations for use of several approved
rapid diagnostic test for syphilis in China and other countries. The
RMMCH is an academic, regional hospital afﬁliated with the University of Witwatersrand. In 2018, there were an average of 1075 babies
born per month, with a perinatal mortality rate of 28.9/1000 births.

2.2.1. Sub-study 1 - A retrospective laboratory evaluation of diagnostic
accuracy using stored plasma samples in China
Specimen collection: Between June-December 2017, pre-characterised stored plasma samples were retrieved from the NCSC laboratory
in Nanjing, China. The samples were selected on the basis of treponemal (TPHA) and non-treponemal (RPR) reactivity for diagnosis of
active syphilis as speciﬁed in the WHO TPP. Three sample types were
selected: (i) active syphilis (TPHA positive, RPR 8); (ii) past treated
(TPHA positive, RPR negative); and (iii) no syphilis (TPHA negative,
RPR negative). We obtained ethics approval from the Alfred Hospital
ethics committee in Melbourne (AHEC #220/15) and the Institute of
Dermatology, Chinese Academy of Medical Science (#2016-016).
Reference tests: Selected samples stored at 80 °C were thawed
and underwent conﬁrmatory testing with TPHA and RPR laboratorybased reference tests following the manufacturer’s instructions to
conﬁrm pre-characterized syphilis status. Discordant results were
retested and samples that remained discordant upon retesting were
excluded and additional samples were requested. Only samples with

Fig. 1. Testing procedure and result window of TP-IgA POCT.
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concordant conﬁrmatory test results for both treponemal and nontreponemal components were included in the ﬁnal sample panel
used for the study.
Testing procedure: After conﬁrmatory testing, each sample of the
ﬁnal sample panel was tested with three different syphilis POCTs: the
TP-IgA POCT (index test), and two syphilis total antibody tests the Alere DetermineTM Syphilis TP test (Abbott Diagnostics, UK) and
the VisitectÒ Syphilis test (Omega Diagnostics, UK). The two latter
tests were selected because these were among the most commonly
used rapid POCT for syphilis with good diagnostic performance[14]
and we could not obtain the DPP Syphilis Screen & Conﬁrm test for
this study. All tests were performed by laboratory technicians following manufacturer’s instructions; results were read and recorded independently of each other.
2.2.2. Sub-study 2 a prospective evaluation of potential clinical utility
using fresh venous blood samples in South Africa
Specimen collection: Between June-December 2018, venous blood
samples were consecutively collected from consenting pregnant or
peripartum women (within two weeks of miscarriage, termination of
pregnancy or childbirth), aged 18 years or older, attending obstetric
and gynaecology department at the RMMCH in Johannesburg, South
Africa. Each participant provided 3 ml venous blood collected in
EDTA tubes for standard syphilis serology (reference) tests and the
index test performed in duplicate by two independent test operators.
Ethics approval was obtained from AHEC (#556/17) and the Human
Research Ethics Committee of the University of Witwatersrand in
South Africa (#R14/49). All participants provided signed informed
consent.
Reference tests: A combination of a treponemal test (TPHA) and a
non-treponemal test (RPR) was used as standard laboratory-based
reference testing for diagnosis of active syphilis infection. For the
treponemal component, the ADVIA Centaur Syphilis assay (Siemens
Healthcare Diagnostics, Tarrytown, NY, USA) was used and for the
non-treponemal component, we used the RPR (Omega Diagnostics,
UK) test. As per standard of care at the study site, a woman who had
reactive results for both TPHA and RPR tests (any titre) was deﬁned
as having active syphilis; a reactive TPHA and non-reactive RPR indicate past/treated syphilis; a non-reactive TPHA and a reactive RPR is
biologically false positive; and non-reactive results to both tests is no
syphilis.
Testing procedure: All blood specimens were processed within
24 h of venepuncture by standard reference and the TP-IgA POCT
assays. The index tests were performed in duplicate by two independent trained laboratory technicians at the RMMCH’s research laboratory. Results of the index test were obtained and recorded in a
blinded fashion, independent from each other and independent of
the reference tests, which were performed at an offsite laboratory.
2.3. Statistical analysis
For sub-study 1, we used a purposively selected quota-sample of
458 specimens (154 active syphilis, 153 past-treated syphilis and 151
healthy control). This sample size would be adequate to estimate
diagnostic accuracy of the TP-IgA POCT, with 95% conﬁdence level, at
the precision of estimates of 5% and 7% and expected sensitivity and
speciﬁcity of 90% and 80%, respectively [15]. For sub-study 2, we
aimed to test diagnostic performance of the TP-IgA POCT in identifying active syphilis using pre-determined values of 96% sensitivity and
85% speciﬁcity, based on the results of sub-study 1. We calculated
that a sample size of 500 would provide 99% conﬁdence with 90%
power to detect a difference of 4% from the presumptive value of 96%
for sensitivity and, 95% conﬁdence with 80% power to detect a difference of 5% from the presumptive value of 85% for speciﬁcity [15].
Diagnostic performance of the TP-IgA POCT was assessed by calculating sensitivity, speciﬁcity, positive predictive value (PPV) and

negative predictive value (NPV) against standard syphilis serology
tests. Speciﬁcally, to assess the performance of the index test as a
non-treponemal conﬁrmatory test for active syphilis, we compared
TP-IgA positivity identiﬁed by naked eye with results of RPR. To
ascertain the test capacity in distinguishing between active and past
syphilis, we compared results of the index test to that of standard reference tests using a combination of treponemal (TPHA) and nontreponemal (RPR) tests. Performance of the TP-IgA test was also compared to that of the DetermineTM and VisitectÒ syphilis POCTs using
pre-characterised plasma samples (sub-study 1 only). Agreement
between duplicate index tests was assessed using kappa statistics
(sub-study 2 only). Numbers of invalid (no control line) and/or indeterminate test results (test operator cannot determine whether or
not a test line was present in the test window) were reported. All
data analysis was performed with Stata version 15¢0.

2.4. Role of funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.
The corresponding author had full access to all the data in the study
and had ﬁnal responsibility for the decision to submit for publication.

3. Results
3.1. Sub-study 1: Diagnostic accuracy study
After conﬁrmatory testing, the ﬁnal panel consisted of 154 active
syphilis (TPHA positive, RPR 8), 153 past-treated syphilis (TPHA
positive, RPR negative) and 151 no syphilis (TPHA and RPR negative)
samples (Table S1-Suplementary ﬁle). These samples came from an
age range of 2 to 81 years (median: 37, IQR: 15, 70); 47% female and
53% male.
Tables 1 and 2 depict the overall results of the TP-IgA POCT using
pre-characterised plasma samples following the WHO TPP categorisation [12]. Among 458 samples tested, four returned indeterminate
TP-IgA test results, of which, three samples were characterised as
past-treated (TPHA+/RPR-) and one was active syphilis (TPHA+/RPR
+8) (Table S1). With the remaining 454 samples, when compared to
RPR, the TP-IgA test demonstrated 96¢1% (95%CI=91¢7% 98¢5%) sensitivity and 84¢7% (95%CI=80¢1 88¢6%) speciﬁcity for identiﬁcation of
active syphilis infection (Table 1). Using a combination of TPHA and
RPR as reference, 71% (107/150) of past syphilis samples (TPHA
+/RPR-) returned a negative result with the TP-IgA whereas, as
expected, 92% (133/145) and 100% (153/153) of these samples were
reactive with the VisitectÒ and DetermineTM POCTs, respectively
(Table 2). All 154 active syphilis samples returned reactive results
when tested with VisitectÒ and DetermineTM POCTs. Three syphilis
negative samples that were reactive with TP-IgA were non-reactive
with the two screening tests (Table S1).

Table 1
Comparison of the TP-IgA POCT with RPR reference test results using pre-characterised stored plasma samples in China (N = 454).
TP-IgA

Positive
Negative
Total

RPR reference

Analytical Performance% (95%CI)

RPR+ 8

Negative

Total

147
6
153

46
255
301

193
261
454*

Sensitivity: 96¢1% (91¢7% 98¢5%)
Speciﬁcity: 84¢7% (80¢1% 88¢6%)
Positive Predictive Value (PPV):
76¢2% (69¢5% 82%)
Negative Predictive Value (NPV):
97¢7% (95¢1% 99¢2%)

* Four indeterminate IgA test results excluded from analysis.
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Table 2
Performance of the TP-IgA POCT and two other POCTs in identifying active syphilis and distinguishing between active and
past, treated syphilis using pre-characterised stored plasma samples in China (N = 454).
Assays/Reference

Active syphilis TPHA+/RPR+ 8

TP-IgA
Positive
147
Negative
6
Total
153*
DetermineTM Syphilis
Positive
154
Negative
0
Total
154
VisitectÒ Syphilis
Positive
154
Negative
0
Total
154

Past/treated TPHA+/RPR-

No syphilis TPHA-/RPR-

Total

43
107
150*

3
148
151

193
261
454

153
0
153

1
149
150*

308
149
457

133
12
145*

4
145
149*

291
157
448

* Four (IgA), one (DetermineTM ) and ten (VisitectÒ ) indeterminate rapid test results excluded from analysis.

3.2. Sub-study 2: Clinical utility study

4. Discussion

Using fresh venous blood samples from prospectively recruited
pregnant/postpartum women in South Africa (N = 503), the TP-IgA
POCT detected all seven RPR positive samples (four RPR 8 and three
RPR<8) but also a small number of samples (3/503 or 0¢6%) that were
negative for RPR (Table 3).
Combining total antibody (TPHA) and RPR testing (Table 4), 5/503
(1%) subjects were diagnosed with active syphilis using the reference
tests (TPHA+, RPR+). The TP-IgA test correctly identiﬁed 100% samples with active syphilis (5/5) and 99% (484/487) samples with no
syphilis infection, and importantly was able to discriminate 9/9 pasttreated syphilis cases (TPHA+, RPR-). The TP-IgA test detected 3/503
samples (0¢6%) that were negative by reference tests and an additional two samples that were deemed biological false positives
(TPHA-/RPR+) (Flowchart Supplementary ﬁle).
The duplicate TP-IgA tests performed by separate operators delivered nearly identical results (99¢8% agreement, kappa=0¢95,
p<0.0001) with only one discordant result for which the reference
tests were negative (TPHA-/RPR-) (Table S2 Supplementary ﬁle).

In addressing the WHO TPP for a syphilis conﬁrmatory test, the
primary intended use of the TP-IgA POCT is an alternative to laboratory-based non-treponemal (RPR) testing, used in combination with
a syphilis total antibody (treponemal) screening test. Results of the
present studies show that the prototype TP-IgA POCT meets the
WHO TPP for a conﬁrmatory POCT for active syphilis, with clinical
sensitivity and speciﬁcity greater than 95% and 80%, respectively. The
TP-IgA POCT can potentially be a useful diagnostic tool for conﬁrmation of active syphilis infections at the point-of-care in resource-constrained settings where both the availability of and access to
laboratory services are limited. In addition, it has the potential to signiﬁcantly reduce overtreatment by distinguishing active syphilis
from past/treated syphilis when used in conjunction with a treponemal-speciﬁc total antibody test.
There are many rapid POCTs for syphilis total antibody already
available in the market, including the Alere DetermineTM and VisitectÒ devices examined here. These tests are highly sensitive, affordable and easy to use by healthcare workers in clinical settings with
minimal training [14,16,17]. Yet, because these tests are based on
detection of total treponemal-speciﬁc antibodies they cannot distinguish between active and past-treated infections. Use of these tests
without conﬁrmatory testing for active syphilis is not only contrary
to policy in many countries, but introduces the risk of unnecessary
treatment of individuals who are treponemal antibody positive due
to previously treated syphilis, and non-treponemal test will be
required for subsequent clinical management [17]. This overtreatment carries public health consequences as it may affect peoples’
willingness to use health services (e.g. antenatal care (ANC) for pregnant women) over fear of being administered unnecessary medications and stigmatisation [18,19]. Overtreatment could also lead to
drug stock-out in resource-constrained, high prevalence settings and
may contribute to the global shortage of Benzathine penicillin [20].

Table 3
Comparison of the TP-IgA POCT with RPR reference test results using fresh
venous blood samples from pregnant/postpartum women in South Africa
(N = 503).
TP-IgA

RPR reference
Positive

Positive
Negative

8
4*
0
4

<8
3*
0
3

Analytical Performance% (95%CI)

Negative

3
493
496

Sensitivity: 100% (59% 100%)
Speciﬁcity: 99¢4% (98¢2% 99¢9%)
PPV: 70% (34¢8% 93¢3%)
NPV: 100% (99¢3% 100%)

10
493
503

* Four samples with RPR titre 8 (one 1:8 & three 1:32); three samples with
RPR titre <8 (two 1:1 & one 1:2).

Table 4
Performance of the TP-IgA POCT in identifying active syphilis and distinguishing between active and past treated syphilis compared to standard laboratory reference testing (TPHA/RPR) using fresh venous blood samples from pregnant/postpartum women in South Africa
(N = 503).
TP-IgA/Reference

Positive
Negative
Total

TPHA+/ RPR-

TPHA-/RPR-

TPHA-/RPR+

RPR8
Active, high titre

TPHA+/RPR+
RPR<8
Active, low titre

Past/ treated syphilis

No syphilis

Biological false positive

4
0
4

1
0
1

0
9
9

3
484
487

2
0
2

Total

10
493
503
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Findings from our studies have some clinical implications for
potential use of the TP-IgA POCT in ﬁeld settings.
First, for the diagnosis of active syphilis with high RPR titre (8),
the use of TP-IgA POCT as a conﬁrmatory test in combination with a
syphilis total antibody POCT could potentially deliver 96% to 100%
sensitivity. This level of sensitivity meets the WHO TPP and is similar
to that of other rapid POCTs for syphilis available on the market that
cannot discriminate past/treated from active syphilis [21]. Diagnosis
of active syphilis, however, could be challenging due to variation in
patient’s clinical manifestations and immune responses at different
stages of syphilis [22]. Subjects with a positive treponemal total antibody test but negative non-treponemal (or in this case TP-IgA) test
for syphilis could have past/treated syphilis, or in a small proportion
could have very early syphilis, long-standing latent syphilis or active
syphilis with negative non-treponemal test [23]. Those latter cases
could potentially be detected using a second but different treponemal
test, and those with two positive treponemal test results and no history of treated syphilis are candidates for treatment [11,24]. Although
clinics in resource-constrained settings may ﬁnd this challenging, it
could still be worth doing given the risk and potential associated cost
of missing cases of untreated infection. Results from our study in
China indicated that six out of 153 active syphilis cases would have
been missed and three out of 151 “no syphilis” cases would have
been unnecessarily treated if only the TP-IgA POCT had been used.
However, if used together with other rapid tests the ﬁrst six cases
would be deemed as requiring treatment and the later three cases
would be deemed biological false positives. We therefore suggest
that the TP-IgA POCT would be most suitable for use in combination
with a standard rapid treponemal total antibody test for diagnosis of
active syphilis infections in clinic settings. This would be an effective
and efﬁcient testing algorithm in settings with limited laboratory
capacity. (Fig. 2)
Second, the diagnosis of syphilis infection with low RPR titre
(TPHA/TPPA +, RPR<8) would be of clinical interest. Although this
serological category is not included in the WHO TPP because RPR
remains stable at low titre in many cases of successfully treated syphilis (serofast reaction), clinical guidelines in many countries dictate
that all patients reactive to both treponemal (TPHA or TPPA) and
non-treponemal tests (RPR) at any titre are considered to have active

syphilis and should be treated. Results of our South Africa study suggested that the TP-IgA POCT could potentially be sensitive enough to
pick up syphilis cases with low RPR titre, enabling same day testing
and treatment at the point-of-care. In addition, the use of the TP-IgA
test in combination with another standard screening test would further identify 71% of past-treated syphilis, signiﬁcantly reducing overtreatment. It is noted that the DPP Syphilis Screen & Conﬁrm test,
although meeting the WHO TPP with a sensitivity of > 85% for detecting samples with high RPR titre (8), does not appear to reduce over
treatment of syphilis [7,8].
Third, current treponemal serological tests for syphilis use native
or recombinant Treponema pallidum antigens to detect IgM and IgG
antibodies to treponemal components [25,26]. They are more sensitive than non-treponemal tests for all stages of syphilis but cannot
distinguish active from past-treated infection and therefore, cannot
be used to monitor the effectiveness of syphilis treatment. Our study
ﬁndings showed that the TP-IgA POCT is highly sensitive, able to distinguish between active and past infections and can potentially be
used for monitoring treatment outcomes. It will also be of interest to
determine the persistence of IgA antibodies in patients with nonvenereal treponemal infections such as non-venereal trepanematoses, which may confound results especially in young subjects from
endemic regions [8]. These particular applications of the TP-IgA
POCT, however, need to be further examined in prospective, longitudinal ﬁeld studies with a ﬁnal manufactured version of the device.
Future studies should also evaluate diagnostic performance of the
test for congenital syphilis and in individuals who have become reinfected as people with repeated episodes of syphilis (e.g. key population at high risk of STIs such as men who have sex with men) may
have different immunological responses compared to those with initial infection [27].
The present studies have some limitations. First, for the China
study we were unable to source the DPP tests to perform a head-tohead comparison with the TP-IgA POCT in identifying active and/or
past/treated syphilis from a pool of pre-characterised stored plasma
samples as originally planned. This makes us unable to draw conclusion on the potential advantage of the TP-IgA POCT compared to the
DPP test in distinguishing between active syphilis and past/treated
infections. Future study to directly compare the two tests for this

Fig. 2. Standard laboratory-based and proposed Point-of-care testing algorithms for diganosis of active syphilis among pregnant women.
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purpose is needed. Second, for the South Africa study, there was a
low prevalence of active and/or past/treated syphilis among the study
population and no clinical data were collected so that the categorisation of syphilis status was solely based on serological tests, which
introduces some uncertainty and limits the generalisation of study
ﬁndings. Third, both studies were conducted in a laboratory environment with trained technical staff and using venous blood (either
fresh or plasma) rather than ﬁnger-prick samples that would be
more likely to be used in ﬁeld settings. Therefore, future studies are
needed to examine diagnostic accuracy of the TP-IgA POCT, as performed by health care worker in clinical settings, with different sample types.
In conclusion, our evaluation studies showed that the prototype
TP-IgA has met the WHO TPP performance criteria for a POCT for conﬁrmatory diagnosis of active syphilis infections. The test demonstrated
its potential utility as an accurate conﬁrmatory test when used in combination with a treponemal total antibody-screening test. Further
study is warranted to assess diagnostic performance of the ﬁnal manufactured test as well as its clinical utility in real world settings.
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